News >

Combinations Take Hold in Kidney Cancer

Angelica Welch
Published: Monday, May 07, 2018

Bradley A. McGregor, MD

Bradley A. McGregor, MD
The recent success seen with the combinations of nivolumab (Opdivo) plus ipilimumab (Yervoy) as well as atezolizumab (Tecentriq) plus bevacizumab (Avastin) has convinced many that this is the era of combinations in kidney cancer, says Bradley A. McGregor, MD. However, the renewed interest and excitement in combinations was started by the success of the combination of lenvatinib (Lenvima) and everolimus (Afinitor), he adds.

The combination of lenvatinib and everolimus as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogenic therapy was approved by the FDA in May 2016. The decision was based on a phase II trial, known as Study 205, in which the combination reduced the risk of progression or death by 63% versus everolimus alone.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication